Gilder Gagnon Howe & CO LLC Krystal Biotech, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $96 - $128	-1 Reduced 0.01%	7,527 $933,000
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $2,712 - $3,255	25 Added 0.33%	7,528 $873,000
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $147,228 - $244,480	1,876 Added 33.34%	7,503 $880,000
Q1 2023 May 15, 2023	BUY	$72.39 - $84.27 $407,338 - $474,187	5,627 New	5,627 $450,000
Q2 2021 Aug 16, 2021	SELL	$62.14 - $81.82 $420,625 - $553,839	-6,769 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$59.42 - $85.46 $831 - $1,196	-14 Reduced 0.21%	6,769 $521,000
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $14,752 - $22,280	-363 Reduced 5.08%	6,783 $407,000
Q3 2020 Nov 16, 2020	SELL	$37.76 - $48.49 $10,384 - $13,334	-275 Reduced 3.71%	7,146 $308,000
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $273,429 - $443,040	7,384 Added 19956.76%	7,421 $307,000
Q1 2020 May 15, 2020	BUY	$35.02 - $65.64 $525 - $984	15 Added 68.18%	37 $2,000
Q3 2019 Nov 14, 2019	BUY	$34.72 - $51.3 $763 - $1,128	22 New	22 $1,000

302

24.5M

444K

325K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.93B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.